04671cam a2200697Ii 4500 ocn779616898 OCoLC 20171115090956.0 m o d cr ||||||||||| 120309t20122012gw a ob 001 0 eng d 9783527644827 (oBook) 3527644822 (oBook) 9783527644797 (ePDF) 3527644792 (ePDF) 9783527644780 (ePub) 3527644784 (ePub) 9783527644803 (Mobi) 3527644806 (Mobi) 128345422X 9781283454223 9783527328499 (print ; alk. paper) 3527328491 (print ; alk. paper) AU@ 000049014070 DKDLA 820120-katalog:000601021 NZ1 14694101 NZ1 15916291 DEBBG BV043394342 AU@ 000059228061 (OCoLC)779616898 (OCoLC)778622647 (OCoLC)781540190 (OCoLC)785779913 (OCoLC)817058699 (OCoLC)824108355 (OCoLC)961501435 (OCoLC)962591607 10.1002/9783527644827 Wiley InterScience http://www3.interscience.wiley.com DG1 eng rda pn DG1 N$T E7B YDXCP OCLCQ OCLCF MMU OCLCQ OCLCO NLGGC IDEBK COO OCLCQ DEBBG EBLCP MAIN RS431.P75 QU 55 MED 071000 bisacsh 615.3 23 Therapeutic proteins : strategies to modulate their plasma half-lives / edited by Roland Kontermann. [electronic resource] Weinheim, Germany : Wiley-Blackwell, an imprint of John Wiley & Sons, 2012. ©2012 1 online resource (374 pages) : illustrations (some color) text txt rdacontent computer c rdamedia online resource cr rdacarrier Includes bibliographical references and index. General information -- Half-life modulating strategies : an introduction -- Pharmacokinetics and half-life of protein therapeutics -- Half-life extension through chemical and post-translational modifications -- Half-life extension through PEGylation -- Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics -- Half-life extension through O-glycosylation -- Polysialic acid and polysialylation to modulate antibody pharmacokinetics -- Half-life extension through HESylation -- Half-life modulation involving recycling by the neonatal Fc receptor -- The biology of the neonatal Fc receptor (FcRn) -- half-life extension by fusion to the Fc region -- Monomeric Fc fusion technology: an approach to create long-lasting clotting factors -- The diverse roles of FcRn: implications for antibody engineering -- Half-life extension by fusion to recombinant albumin -- AlbudAb technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives -- Half-life extension by binding to albumin through an albumin binding domain -- Half-life extension by binding to albumin through small molecules -- Half-life extension with pharmaceutical formulations -- Half-life extension with pharmaceutical formulations: liposomes -- Half-life extension with pharmaceutical formulations: nanoparticles by the miniemulsion process. For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals. Online resource; title from resource home page (ebrary, viewed on June 17, 2014). Protein drugs Design. Proteins Therapeutic use. Proteins pharmacokinetics. Half-Life. MEDICAL Pharmacology. bisacsh Protein drugs Design. fast (OCoLC)fst01079680 Proteins Therapeutic use. fast (OCoLC)fst01079767 Electronic books. Kontermann, Roland, 1961- editor. Print version: Therapeutic proteins. Weinheim, Germany : Wiley-VCH, ©2011 9783527328499 (DLC) 2012540834 (OCoLC)768072878 http://onlinelibrary.wiley.com/book/10.1002/9783527644827 Wiley Online Library ddc BK 205704 205704